Trials / Completed
CompletedNCT01496937
First-in-Human Exploratory Single Ascending Dose of GLPG0974
Exploratory Double-blind Placebo-controlled Study for the Assessment of Pharmacokinetics (PK), Safety, Tolerability, and Pharmacodynamics (PD) of Single Ascending Oral Doses of GLPG0974 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this exploratory first-in-human study is to evaluate the amount of GLPG0974 present in the blood (pharmacokinetics) after single oral doses of GLPG0974 given to healthy subjects. Furthermore, during the course of the study, safety and tolerability as well as the effects of GLPG0974 on mechanism of action-related parameters in the blood (pharmacodynamics) will be characterized compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG0974 | |
| DRUG | GLPG0974 |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2012-01-01
- Completion
- 2012-02-01
- First posted
- 2011-12-21
- Last updated
- 2012-04-19
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT01496937. Inclusion in this directory is not an endorsement.